Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 66 clinical trials
Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)

  • 0 views
  • 19 Feb, 2024
A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

An open-label, randomised, controlled, multi-centre, trial with disease free survival as the primary end point. The worldwide collaboration is referred to as GLOBAL BALLAD and consists of a number of individual parallel prospective studies addressing the same objectives with similar designs brought together under the framework of the International Rare …

adjuvant
serum bilirubin level
adjuvant chemotherapy
blood transfusion
cancer
  • 0 views
  • 19 Feb, 2024
Neoadjuvant RCT Versus CT for Patients With Locally Advanced Potentially Resectable Adenocarcinoma of the GEJ

This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing neoadjuvant radiochemotherapy with FLOT versus FLOT chemotherapy alone fr patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ)

tubal occlusion
leucovorin
hormonal contraception
adenocarcinoma of the gastroesophageal junction
oxaliplatin
  • 0 views
  • 19 Feb, 2024
PAXG Out in the Country

The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.

neutrophil count
pdac
ductal adenocarcinoma
absolute neutrophil count
cisplatin
  • 0 views
  • 19 Feb, 2024
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate …

breast cancer
neutrophil count
cancer
bisphosphonate
HER2
  • 0 views
  • 19 Feb, 2024
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …

gilbert's syndrome
chemoradiotherapy
nivolumab
gemcitabine
carcinoma
  • 0 views
  • 19 Feb, 2024
4SCAR-CD44v6 T Cell Therapy Targeting Cancer

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.

  • 0 views
  • 19 Feb, 2024
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma

Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations before and after surgery.

hepatitis b
cytostatic
gastric adenocarcinoma
gastric tumor
leucovorin
  • 0 views
  • 19 Feb, 2024
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

vitiligo
hypothyroidism
type 1 diabetes mellitus
TACE
hepatocellular carcinoma
  • 0 views
  • 19 Feb, 2024
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

metastatic hormone refractory prostate cancer
bone disease
prostate adenocarcinoma
cabozantinib
castration-resistant prostate cancer
  • 0 views
  • 19 Feb, 2024